rs730880608
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP3_Strong
The NM_000256.3(MYBPC3):c.3796T>C(p.Cys1266Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C1266Y) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.3796T>C | p.Cys1266Arg | missense_variant | 33/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3796T>C | p.Cys1266Arg | missense_variant | 33/35 | 5 | NM_000256.3 | ENSP00000442795 | P4 | |
MYBPC3 | ENST00000399249.6 | c.3796T>C | p.Cys1266Arg | missense_variant | 32/34 | 5 | ENSP00000382193 | A2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 24, 2015 | p.Cys1266Arg (C1266R) TGC>CGC: c.3796 T>C in exon 33 of the MYBPC3 gene (NM_000256.3)The C1266R mutation in the MYBPC3 gene has been reported with another MYBPC3 mutation (E1265V) in one 46-year-old male with a diagnosis of HCM (Maron B et al., 2012). Maron et al. (2012) reported this mutation was not observed in 300 unrelated healthy, ethnically-matched chromosomes. Furthermore, the C1266R mutation was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. C1266R results in a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. A mutation in the same residue (C1266Y) and mutations in nearby residues (G1260D, C1264F, E1265V, L1268Q) have been reported in association with cardiomyopathy, further supporting the functional importance of this residue and region of the protein. The variant is found in HCM panel(s). - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 06, 2018 | The p.C1266R variant (also known as c.3796T>C), located in coding exon 33 of the MYBPC3 gene, results from a T to C substitution at nucleotide position 3796. The cysteine at codon 1266 is replaced by arginine, an amino acid with highly dissimilar properties. This variant has been detected in conjunction with a different alteration in MYBPC3 in a patient with hypertrophic cardiomyopathy (HCM) (Maron BJ et al. Heart Rhythm. 2012 Jan;9:57-63). Other alterations involving the same amino acid, including p.C1266Y (c.3797G>A) and p.C1266W (c.3798C>G), also have been reported in HCM cohorts; however, clinical details were limited (Page SP et al. Circ Cardiovasc Genet. 2012 Apr;5:156-66; Lopes LR et al. Heart, 2015 Feb;101:294-301; Walsh R et al. Genet. Med., 2017 02;19:192-203). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at